Australia markets open in 8 hours 48 minutes

Inovio Pharmaceuticals, Inc. (INO)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
10.58+0.86 (+8.85%)
At close: 4:00PM EST

10.46 -0.12 (-1.13%)
Before hours: 9:12AM EST

Full screen
Trade prices are not sourced from all markets
Previous close9.72
Open9.80
Bid10.36 x 2900
Ask10.40 x 800
Day's range9.50 - 10.68
52-week range3.14 - 33.79
Volume17,794,201
Avg. volume11,541,222
Market cap2.164B
Beta (5Y monthly)1.08
PE ratio (TTM)N/A
EPS (TTM)-1.32
Earnings date09 Nov 2020
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est12.29
  • INOVIO Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
    PR Newswire

    INOVIO Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares

    INOVIO Pharmaceuticals, Inc. (Nasdaq: INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases, including COVID-19, cancer and HPV-associated diseases, today announced the closing of its previously announced underwritten public offering of 20,355,000 shares of its common stock, which includes 2,655,000 shares sold pursuant to the underwriters' exercise in full of their option to purchase additional shares, at a price to the public of $8.50 per share. The gross proceeds to INOVIO from the offering, before deducting underwriting discounts and commissions and offering expenses, were approximately $173 million.

  • What Is The Ownership Structure Like For Inovio Pharmaceuticals, Inc. (NASDAQ:INO)?
    Simply Wall St.

    What Is The Ownership Structure Like For Inovio Pharmaceuticals, Inc. (NASDAQ:INO)?

    If you want to know who really controls Inovio Pharmaceuticals, Inc. ( NASDAQ:INO ), then you'll have to look at the...

  • INOVIO Announces Pricing of Public Offering of Common Stock
    PR Newswire

    INOVIO Announces Pricing of Public Offering of Common Stock

    INOVIO Pharmaceuticals, Inc. (Nasdaq: INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases, including COVID-19, cancer and HPV-associated diseases, today announced the pricing of an underwritten public offering of 17,700,000 shares of its common stock at a public offering price of $8.50 per share. In addition, INOVIO has granted the underwriters a 30-day option to purchase up to an additional 2,655,000 shares of common stock at the public offering price, less underwriting discounts and commissions. Gross proceeds to INOVIO from the offering are expected to be approximately $150.5 million, before deducting underwriting discounts and commissions and estimated offering expenses, but excluding any exercise of the underwriters' option. All of the shares are being sold by INOVIO.